Abstract Neuroblastoma (NB) is an aggressive pediatric cancer that originates from neural crest tissues of the sympathetic nervous system. NB is highly heterogeneous both from a clinical and a molecular perspective. Clinically, this cancer represents a wide range of phenotypes ranging from spontaneous regression of 4S disease to unremitting treatment-refractory progression and death of highrisk metastatic disease. At a cellular level, the heterogeneous behavior of NB likely arises from an arrest and deregulation of normal neural crest development. In the present review, we summarize our current knowledge of neural crest development as it relates to pathways promoting 'stemness' and how deregulation may contribute to the development of tumor-initiating CSCs. There is an emerging consensus that such tumor subpopulations contribute to the evolution of drug resistance, metastasis and relapse in other equally aggressive malignancies. As relapsed, refractory disease remains the primary cause of death for neuroblastoma, the identification and targeting of CSCs or other primary drivers of tumor progression remains a critical, clinically significant goal for neuroblastoma. We will critically review recent and past evidence in the literature supporting the concept of CSCs as drivers of neuroblastoma pathogenesis.
Introduction
Neuroblastoma (NB) is a pediatric solid tumor of neural crest origin that encompasses between 8 and 10% of all pediatric cancers and up to 15% of all pediatric cancer deaths (Goodman et al. 1999) . Treating NB remains a significant challenge due to the heterogeneous course the disease follows, ranging anywhere from spontaneous regression to treatmentresistant progression and death (Castleberry 1997) . High-risk NB, usually metastatic disease with unfavorable histology and high-risk genetic modifications, poses the most significant challenge to treatment (Cohn et al. 2009 ). Despite intensive induction chemotherapy, radiation therapy and surgery, the long-term survival for patients with high-risk NB remains less than 50% and less than 10% in those patients that suffer disease relapse (Maris et al. 2007 ). The biological heterogeneity seen in NB largely correlates with tumor histology and differentiation status.
Histologically, NB tumors consist of two cell types, neuroblastic ganglionic cells and reactive Schwannian stromal cells and can be classified into four basic morphologies . These morphologies consist of ganglioneuroma (Schwannian stroma-dominant), intermixed ganglioneuroblastoma (Schwannian stroma-rich), nodular ganglioneuroblastoma (composite tumor composed of aggressive and non-aggressive clones) and neuroblastoma (Schwannian stroma-poor). These morphologic characterizations are thought to represent levels of tumor differentiation mediated by chemotaxis of Schwann cells that secrete antiproliferative and differentiating factors onto the neuroblasts (Liu et al. 2005) . During differentiation and maturation, a majority of neuroblasts will die before reaching maturity, leaving a persistent and dominant Schwannian stroma. Thus, ganglioneuromas represent a NB that has fully matured and differentiated (Shimada and Roald 2000) . While the factors that lead a NB tumor to recruit Schwann cells and differentiate remains unknown, retinoic acid therapies have been used as maintenance therapies to differentiate residual disease with significant increase in patient event-free survival . Recent findings from single-cell analyses and global transcriptional profiling are beginning to shed light on the molecular control of tumor heterogeneity (Louis and Shohet 2015; van Groningen et al. 2017) . Taken together, NB represents a tumor of developmental arrest and delayed differentiation. Understanding the normal development of the neural crest-derived sympathoadrenal system can help us understand and identify the pathways involved in the maintenance of undifferentiated clones of tumor initiating neuroblasts.
Neural crest development and NB

Neural crest is a multipotent transient embryonic tissue
The neural crest (NC) is a transient embryonic cell population that arises during gastrulation and neurulation and migrates extensively throughout the developing embryo, differentiating into diverse tissues including much of the craniofacial skeleton, sympathetic and peripheral nervous system, adrenal chromaffin cells and melanocytes. The complexity of tissues derived from the NC suggests the presence of multipotent progenitors. Indeed, early investigation into the potency of NC precursors discovered that injection of lineage tracers into NC precursors within avian embryos found that NC was multipotent; however, this technique was limited by technical challenges of intracellular injections Fraser 1988, 1989) . Using advances in lineage tracing models, the R26R-Confetti mouse model, investigators were able to identify that both individual pre-migratory and migratory NC cells were multipotent rather than pools of fate-restricted progenitors (Baggiolini et al. 2015) . Development, maintenance and differentiation of this multipotent cell population is a highly complex process and, correspondingly, NC induction, speciation, delamination and differentiation are tightly controlled pathways orchestrated by a multifaceted gene regulatory network (Sauka-Spengler and Bronner-Fraser 2008) . Initiating mutations or derangements during any number of these processes may generate tumor-initiating neuroblasts. As detailed below, signaling pathways and transcription factors regulating various aspects of NC development are also implicated in NB pathogenesis clinical phenotypes.
NC induction
NC development begins during gastrulation with formation of tissues involved in neural tube development. The primitive neural tube consists of non-neural ectoderm and neural plate (NP) tissues with the junction giving rise to the neural plate border (NPB). Induction of genes within this NPB leads to the expression of NC specifier genes. Induction is mediated by interconnected signaling pathways of bone morphogenic protein (BMP), Wingless/Int (WNT), Fibroblast growth factor (FGF) and to a lesser extent Notch/Delta signaling. This induction activates key transcription factors that specify the NPB and prime the NPB tissue for induction of genes that allow for NC speciation.
BMP in NC induction
BMP is a protein from the transforming growth factor beta (TGFß) family that is secreted by neighboring nonneural ectoderm. Signaling through BMP receptors activates the Smad family of transcription factors and leads to transcription of genes involved in growth and differentiation (Miyazono et al. 2005) . Studies using BMP gradients have shown that NPB speciation occurs in regions with intermediate BMP levels (Marchant et al. 1998) . Using a NC-specific conditional knockout of BMP signaling (Pax3-Cre-BMPR1a) in mice, researchers found that mice without NC BMP had no detectable cranial or truncal NC, as determined by Cad6 and Sox10 expression, respectively (Stottmann and Klingensmith 2011) . Using a human ESC model, early inhibition of BMP (days 0-2) with antagonist noggin led to a significant decrease in NC induction whereas later inhibition with noggin (days 3-4) only had a partial reduction in induction (Leung et al. 2016) . These studies indicate that early and consistent BMP expression is essential for NC induction.
In NB, BMP has been associated with NB differentiation. In the IMR-32 NB cell line, combination therapy using BMP-6 and retinoic acid derivatives led to synergistic differentiation of NB cell lines into dopaminergic neurons as evidenced by increased expression of tyrosine hydroxylase, morphological neuronal maturation and inability to resume cell division (Sumantran et al. 2003) . Furthermore, incubation of mouse NB cell line Neuro2a with BMP2 led to a decrease in Id expression (inhibitor of differentiation; discussed below) and upregulation of neural specific transcription factors (Dlx2, Brn3a, NeuroD6) promoting the differentiation of NB cell lines to neural lineages (Du and Yip 2010) . Thus, suppression of BMP signaling may represent a pathway derangement to maintain multipotency in NB.
Wnt pathway in NC induction
Wnt is a secreted ligand that controls ß-catenin signaling. Wnt binds to Frizzled and related receptors, leading to activation of Disheveled and inhibition of the GSK3ß/axin complex that normally targets ß-catenin for degradation. Stabilization of ß-catenin allows it to translocate to the nucleus and act as a co-activator with WNT effector TCF/LEF (MacDonald et al. 2009 ). Secretion of Wnt by neighboring non-neural ectoderm allows it to bind to Frizzled receptors expressed on cells of the NPB, leading to induction of ß-catenin genes associated with NC speciation. In Xenopus and avian models, expression of Wnt pathway components within ectoderm explants was sufficient to drive the expression of NC markers (Abu-Elmagd et al. 2006; Chang and Hemmati-Brivanlou 1998; GarciaCastro et al. 2002) . Furthermore, blocking Wnt signaling axis (activation GSK3ß or knockdown Frizzled/Wnt) led to the loss of cells with NC marker expression (FoxD3, Snail2) (Tan et al. 2001) . Activation of Wnt signaling, through repression of GSK3ß, in human embryonic stem cells (hESCs) led to a rapid differentiation into neural crest-like cells as evidenced by expression of NC markers SOX10, PAX7 and TFAP2A (Leung et al. 2016) . These data suggest that canonical Wnt signaling is both sufficient and necessary for NC induction.
Deregulation of Wnt signaling has been shown to stimulate proliferation and maintenance of CSC populations in many cancers including colorectal cancer, hepatocellular carcinoma, medulloblastoma and some leukemias (Cordeiro et al. 2014; Dong et al. 2016; Dow et al. 2015; Petropoulos et al. 2008; Wang et al. 2016) . However, studies in NB have shown conflicting evidence for the role of the Wnt pathway in tumorigenesis. Using an IGR-N-91 xenograft model, cell lines derived from the primary tumor and two metastatic foci showed a decrease in Wnt-5a expression that was reversed by retinoic acid differentiation therapy; however, the effects were due to signaling through the non-canonical calcium-dependent signaling pathway involving protein kinase C theta (PKC-θ) (Blanc et al. 2005) . Studies in NB cell line SK-N-SH have shown differential gene expression of Wnt pathway components within a CD133+ NB CSC-like population (described below) and, furthermore, activation of canonical Wnt signaling through ß-catenin in this subpopulation led to in vitro doxorubicin resistance (Vangipuram et al. 2012) .
FGF pathway in NC induction
Fibroblast growth factor (FGF) is a secreted protein that binds and signals through receptor tyrosine kinases, also known as fibroblast growth factor receptors (FGFRs). Signaling through FGFRs activates many downstream pathways involved in proliferation and survival, including Ras/ERK and Akt/ MTOR (Ornitz and Itoh 2015) . In NC induction, FGF is released by the paraxial mesoderm and acts on FGFRs in the NPB. In Xenopus, zebrafish and chick models, overexpression of FGF8 ligands or their receptors led to NC marker expression via inhibition of BMP signaling and induction of Wnt signaling (Furthauer et al. 1997; Hong et al. 2008; MonsoroBurq et al. 2003; Wilson et al. 2000) . Conversely, inhibition FGF signaling through the expression of a dominant negative FGFR1 led to a loss in cells with NC marker expression (Mayor et al. 1997) . In chick embryos, ectopic expression of FGF was sufficient to drive the formation of NC-like derivatives (Yardley and Garcia-Castro 2012) . Further studies in Xenopus have shown that FGF signaling through FGFR4 activates STAT3 (signal transducer and activator of transcription 3) and leads to expression of NC border genes and NC specifiers, while loss of FGFR4 prevents this induction (Nichane et al. 2010 ). Thus, FGF may act directly through STAT3 activation, or indirectly through BMP pathway inhibition and Wnt pathway activation.
Signal transducer and activator of transcription 3 (STAT3) is an important transcription factor involved in the activation and regulation of genes related to proliferation, apoptosis and tissue differentiation (Villarino et al. 2015) . In multiple CSC models, including neural tumors such as glioblastoma, STAT3 has been shown to activate transcription factors associated with pluripotency and contribute to the maintenance of CSCs (Sherry et al. 2009 ). In NB cell lines, transgenic mouse models and primary patient samples, expression of STAT3 downstream of the granulocyte stimulating factor receptor (G-CSFR) is associated with a NB CSC-like subpopulation with increased tumorigenicity and chemoresistance (Hsu et al. 2013 ) (discussed below). Furthermore, treatment of NB cell lines and xenograft tumor models with STAT3 inhibitor Stattic led to decreased tumorigenicity, decreased metastasis and reduction in chemoresistance (Agarwal et al. 2015) . Treatment of NB cell lines NGP and IMR-32 in vitro with STAT3 targeted antisense oligonucleotide AZD9150 led to decreased cell proliferation. In vivo, treatment of xenograft tumors with AZD9150 greatly reduced re-implantation potential of NB tumors indicating the importance of STAT3 in NB tumor initiation (Odate et al. 2017) .
Notch pathway in NC induction
Notch proteins are transmembrane signaling molecules that act as intracellular receptors for Delta/Jagged protein ligands. Upon binding Delta, the intracellular domain of Notch is cleaved, translocates to the nucleus and binds associated transcription factors to activate transcription of target genes (Hori et al. 2013) . In Xenopus and chick models, Notch cleavage and activation leads to NC induction via attenuation of BMP4 signaling. However, in mouse and zebrafish models, Notch was found to be more important in NC differentiation than induction, where knockout of Notch led to a decrease in truncal NC cell derivatives but not cranial derivatives (Cornell and Eisen , 2002; Hernandez-Lagunas et al. 2011) . Therefore, the role of Notch signaling in NC induction appears to be species-specific but in general maintains the NC progenitor population in a more proliferative state through modulation of other induction signaling pathways.
Notch plays a critical role in embryological development including many pathways that maintain cells in a proliferative state with blocked differentiation. In neural systems, Notch1 is responsible for the maintenance of neural stem cells via regulation of cell cycle exit and prevention of neural differentiation. Here, knockdown of Notch signaling components (RBPj) led to depletion of stem cell pool and premature cessation of neurogenesis (Ables et al. 2010; Ehm et al. 2010; Hitoshi et al. 2002) . In NB, inhibition of Notch1 signaling within the human NB cell line SH-SY5Y led to neuronal differentiation via a JNK-CRT-mediated pathway. Correspondingly, treatment of NB xenograft mice with Notch inhibitors (γ-secretase inhibitors, GSIs) led to suppression of tumor progression (Chang et al. 2010 ). Treatment of SH-SY5Y and IMR-32 human NB cells lines with combination of GSIs and retinoic acid derivatives led to synergistic complete cell growth arrest, neuronal differentiation and reduced cell motility (Ferrari-Toninelli et al. 2010) . Furthermore, expression of constitutively active Notch1 protein in the mouse Neuro2a cell line led to inhibition of both spontaneous and RA-induced cell differentiation (Grynfeld et al. 2000) .
Neural plate border specification
NPB cells have the ability to differentiate into NC, as well as spinal roof plate, dorsal interneurons and sensory neurons. Activation of a regulatory network of homeobox transcription factors confers competence on this region to form NC. These transcription factors can be divided into two groups (early, late) based on their temporal expression. The early factors, Gbx2 and AP2, are expressed during gastrulation and are critical for NP border specification. Both transcription factors are activated by Wnt signaling to induce expression of downstream NP specifiers and the loss of these two factors leads to loss of expression of downstream NC specifier Snail2 (de Croze et al. 2011; Li et al. 2009 ). Msx1 expression is tightly controlled by graded BMP signaling. It functions to activate further NC specifiers, Snail2, FoxD3 and Twist1 and may play a role in suppressing NP markers such as Sox2 (Liu et al. 2004 ). Pax3 and Zic1 are direct activators of critical NC specifiers including Snail1/2, FoxD3 and Sox9 (Plouhinec et al. 2014) . Ectopic expression of both Pax3 and Zic1 in ventral ectoderm led to the formation of NC indicating that these two factors are sufficient to drive NC induction (Monsoro-Burq et al. 2005) . However, expression levels of these factors are tightly controlled as elevated expression drives cells into non-NC fates (Hong and Saint-Jeannet 2007) .
In NB, Msx1 has been shown to modulate both Notch/ Delta signaling and Wnt signaling pathways. Inducible expression of Msx1 in NB cell line SJNB-8 led to inhibition of proliferation and colony formation as well as strong activation of Notch pathway target genes (Revet et al. 2008) . Msx1 was also found to activate transcription of Wnt pathway antagonists; however, these gene products did not interfere with Wnt signaling (Revet et al. 2010) . Pax3 is a well-characterized proto-oncogene (Linardic 2008) . Expression of Pax3 in human NB cell lines (SH-SY5Y, SH-EP1, LA-1-55 N and LA-1-5S) was correlated with more malignant morphologic phenotype. Furthermore, knockdown of Pax3 in these cell lines led to G1 cell cycle arrest and growth inhibition, induction of apoptosis, a decrease in migration and invasion and increased sensitivity to chemotherapy (Fang et al. 2014) . The role of Gbx2 and AP-2 in NB pathogenesis is yet to be elucidated.
Neural crest speciation
Following activation of NPB specifiers and priming of NPB for NC development, activation of a second wave of transcription factors coordinates commitment of NPB cells to the NC lineage and primes these early NC cells for delamination and migration. These factors can be split into two groups based on their function in NC speciation.
Early onset NC specifiers
Factors expressed early in NC speciation are involved in promoting proliferation, suppressing neural differentiation and maintaining these early NC cells in a multipotent state. The main factors involved in progenitor maintenance are c-Myc and its direct downstream target Id3 (inhibitor of differentiation 3). C-Myc and Id3 act to control the cell cycle and mediate balance between proliferation and apoptosis. Loss of both c-Myc and Id3 led to a loss of detectable NC progenitor cells and excess CNS progenitors whereas overexpression led to maintenance of the NC in a prolonged multipotent state (Kee and Bronner-Fraser 2005; Light et al. 2005 ). This indicates the role of c-Myc and Id3 in the maintenance of NC progenitor multipotency.
c-Myc and related N-Myc are transcriptional regulators that are directly involved in the regulation of thousands of genes involved in the maintenance of pluripotency (Chappell and Dalton 2013) . C-Myc was first implicated for its role in pluripotency when it was found activated downstream of LIF/STAT3 signaling (Cartwright et al. 2005) . Myc, one of the four Yamanaka transcription factors used to reprogram terminally differentiated cells into pluripotent stem cells, has the strongest effect on establishing a pluripotent-like gene signature and acts early in the reprogramming process through modulation of epigenetic modulators (Mikkelsen et al. 2008; Sridharan et al. 2009 ). While the expression of c-Myc is normally tightly regulated in embryologic development, deregulation of Myc expression is seen in many cancers (Dang 2012; Gabay et al. 2014) .
Amplification of MYCN leading to N-myc protein overexpression is present in approximately 50% of high-risk tumors (overall incidence is approximately 25% of tumors) (Huang and Weiss 2013) . MYCN amplification, identified over 30 years ago, remains one of the strongest indicators of poor prognosis in high-risk NB. MYCN-amplified tumors are typically high-grade, aggressive cancers consisting of primarily undifferentiated or poorly differentiated neuroblasts (Seeger et al. 1985) . Furthermore, high-risk tumors without MYCN amplification tend to have activated c-Myc or downstream signaling pathways contributing to undifferentiated phenotype. In an analysis of 357 diagnostic patient samples, 38/39 tumors with elevated Myc protein expression occurred without MYCN amplification and protein expression and like MYCN-amplified tumors, Myc-expressiong tumors had unfavorable histology and poor 3-year event-free survival (46.5%) indicating the importance of both MYCN and c-Myc in maintaining an undifferentiated state in NB . Using conditional expression of N-Myc in human NB cell line Tet21N, an unbiased ChIP-chip assay for N-Myc bound genes identified that, in NB, N-Myc regulates genes associated with critical embryonic stem cell factors, including LIF, KLF2, KLF4 and LIN28B (Cotterman and Knoepfler 2009 ).
Late-onset NC specifiers
Late-onset NC specifier genes function to initiate the epithelial to mesenchymal transition allowing NC cells to adopt a migratory phenotype and delaminate. Transcription factors involved in this program include Sox9, Sox 10, FoxD3, Snail 2 and Twist1. Sox9 is activated by Ap2 signaling and is important in initiating the EMT program and, specifically in trunk NC, Sox9 expression promotes NC survival through inhibition of apoptosis and cell cycle arrest via regulation of Snail2 (Cheung and Briscoe 2003; Cheung et al. 2005 ). FoxD3 and Snail2 are critical factors in initiating the EMT program. FoxD3 acts to inhibit expression of N-cadherin and activate expression of Integrin-B1, while Snail 2 acts to inhibit occludins and E-cadherin while also promoting the expression of MMPs (Cheung et al. 2005; Taneyhill et al. 2007 ). Overall, this leads to reduced cell adhesion and increased synthesis of enzymes involved in matrix resorption, freeing the cells for delamination. In addition to activation of the EMT program, Sox10 is known to promote the survival and inhibit multi-lineage differentiation of NC stem cells (John et al. 2011) .
Analysis of 42 primary NB tumor specimens by IHC revealed that higher FoxD3 expression levels correlated with tumors with good differentiation status while RT-PCR and western blotting revealed that 20 primary samples and three human cell lines had lower FoxD3 mRNA and protein levels compared to normal dorsal ganglion (Li et al. 2013) . Ectopic re-expression of FoxD3 in human NB cell lines SH-SH5Y and SK-N-SH led to downstream suppression of genes associated with angiogenesis (VEGF) and invasion (MMP-9) and attenuation of growth, migration, invasion and angiogenesis. Furthermore, ectopic expression of FoxD3 in SH-SY5Y cells led to decreased tumor formation compared to xenografts of cells expression endogenous levels (Li et al. 2013 ). Expression of Snail2 in NB is critical to migration, invasion and metastasis. Activation of Snail2 expression within human NB cell line LA-N-5 was associated with increased migration and invasion through the matrigel membrane (Tanno et al. 2010) . In human NB cell lines LAN-1, SK-N-LP, SK-N-JD, SH-SY5Y and SK-N-AS, expression of Snail2 and cofactor LMO4 is critical in repression of E-Cadherin expression and activation of epithelial to mesenchymal transition (Ferronha et al. 2013) . In an analysis of 144 high-risk primary NB tumor samples, TWIST1 expression in correlated significantly with MYCN and Myc protein expression. Furthermore, in SHEP and Tet21N human NB cell lines, Twist1 was found to be a direct transcriptional target of both N-Myc and c-Myc and functioned to inhibit p53-mediated apoptosis, allowing aberrant cell cycle progression (Selmi et al. 2015) . Sox9 and Sox10 are used as markers of pre-and post-migratory NC in gene expression profiling of NB; however, any role they play in NB tumorigenicity has yet to be elucidated.
Neural crest delamination
NC delamination, also referred to as epithelial to mesenchymal transition (EMT), describes a process by which NC cells lose adhesion to neighboring neuroepithelial cells and acquire a migratory mesenchymal phenotype, allowing the cells to migrate away from the developing neural tube and colonize distant sites for further speciation and differentiation (Lamouille et al. 2014; Theveneau and Mayor 2012) . NC delamination is initiated by NC specifier genes Sox9/10, FoxD3, Snail2 and Twist to promote cell survival, loss of cell-to-cell adhesion, loss of cell-to-matrix adhesion and digestion of extracellular matrix.
The first step in the EMT program is transition in cell-tocell contacts from tight junctions to gap junctions and thus eliminating cell apical to basal polarity. Snail2, activated during NC speciation, downregulates the expression of claudins and occludins, critical mediators of tight junctions that regulate signaling and calcium-dependent adhesion, respectively (Ikenouchi et al. 2003; Shin et al. 2006) . During this time, the cell also undergoes major cytoskeletal rearrangement to switch cadherins from type I (strong) to type II (weak). FoxD3 and Snail2 regulate this process by downregulating N-cadherin and E-cadherin, respectively (Cheung et al. 2005; Taneyhill et al. 2007 ). Coordinated with this, FoxD3 and Sox10 upregulate the expression of type II cadherins, including Cadherin 7 and 11 (Chalpe et al. 2010) .
Once the NC is more mobile, with weak cell-to-cell contacts and weak cell-to-ECM contacts, it begins expressing proteases to digest matrix and allow for migration away from the neural tube. Snail is thought to upregulate the expression of matrix metalloproteinases, although the mechanism in NC is unknown (Miyoshi et al. 2005) . Two key MMPs involved in NC migration are MMP2 and ADAM13. In studies of avian embryos, MMP2 was found to be a critical factor in the NC migration, where pharmacologic inhibition of MMP2 led to a significantly reduced enteric nervous system network ( A n d e r s o n 2 0 1 0 ) . I n X e n o p u s , A D A M 1 3 ( A disintegrating and metalloproteinase 13) is expressed in both premigratory and migratory NC where it assists in detachment from neuroepithelium and cleavage of ECM barriers (Alfandari et al. 2001) . Expression of B1 integrin by Fox3D allows the cell to rapidly assemble and disassemble focal contacts with extracellular matrix, an essential process in directional cell migration (Delannet et al. 1994; Lallier and Bronner-Fraser 1993) .
The process of EMT has long been implicated in cancer, with loss of cell adhesion and upregulation of MMPs as a mechanism of invasion and metastasis (Ye and Weinberg 2015) . Nevertheless, the requirement for EMT pathways and metastasis remains debated and may be tissue-specific (Trimboli et al. 2008; Fischer et al. 2015) . However, increasing evidence now suggests that EMT pathways are enriched within CSCs and may contribute to their tumorigenicity (Mitra et al. 2015) . The process of EMT is dynamic and likely consists of states with a mixed gradient of mesenchymal and epithelial phenotypes. These mixed partial EMT states have been correlated to cell populations with increased aggressiveness and stemness as compared to strict epithelial and mesenchymal states (Jolly et al. 2015) . In NB, general EMT pathways have been associated with the development of drug resistance and correlate with lower overall survival. In an analysis of cisplatin-resistant human NB cell lines, CHP212Cis100, KellyCis83 and SK-N-ASCis24, all resistant lines compared to their cisplatin-sensitive counterparts were found to be enriched in gene pathways of a mesenchymal phenotype, including actin cytoskeleton signaling, integrin-linked kinase signaling and epithelial adherens junction signaling (Piskareva et al. 2015) . In a similar analysis, SK-N-SH and SK-N-BE doxorubicin-resistant cell lines had enriched expression of genes associated with epithelial to mesenchymal transition and had a more invasive phenotype as compared to their parenteral strains (Naiditch et al. 2015) .
Sympathoadrenal speciation
NB arises exclusively within components of the sympathetic nervous system including the adrenal medulla (chromaffin cells) and paraspinal sympathetic ganglia. These cells share a common fate-restricted sympathoadrenal (SA) progenitor that develops from NC cells that have aggregated at the dorsal aorta (Anderson et al. 1991; Shtukmaster et al. 2013) . Following EMT, migratory NC destined to become SA precursors follow a ventral migration pattern from the neural tube and aggregate at the dorsal aorta to form the primary sympathetic ganglia (Loring and Erickson 1987) . BMPs released from the wall of the dorsal aorta are essential for SA speciation and the ability of the progenitors to acquire neuronal and cholinergic properties. Studies in avian and mouse embryos have shown that expression of BMP 2/4/7 in the wall of the dorsal aorta is required for SA speciation and expression of Phox2b, a factor critical to the differentiation of SA progenitors (Reissmann et al. 1996; Schneider et al. 1999) .
Phox2b (paired-like homebox 2b) is a transcription factor expressed in all noradrenergic neurons and is critical for the neurogenesis in the autonomic nervous system. In the absence of Phox2b expression, SA progenitors at the dorsal aorta and primitive adrenal gland lack all markers of autonomic development and lineage except for MASH-1 (Huber et al. 2005; Pattyn et al. 1999 ). Phox2b normally functions in the activation of further SA specifiers including MASH-1, Hand2 and GATA2/3 (Huber et al. 2005) . MASH-1 (mammalian achaetescute homolog 1, now ASCL1, Achaete-scute homolog 1) is a transcription factor activated by BMP signaling that is critical to functional development of the SA system. In the absence of MASH-1, migratory NC still assemble into the primary sympathetic ganglia in the vicinity of the dorsal aorta and undergo partial differentiation; however, they then undergo spontaneous apoptosis leading to eventual loss of the entire autonomic nervous system (Guillemot and Joyner 1993; Hirsch et al. 1998) . MASH-1 functions to activate Phox2a, which activates transcription of genes associated with noradrenergic traits including expression of dopamine biosynthesis enzymes comprising tyrosine hydroxylase (TH) and dopamine beta-hydroxylase (DBH) (Lo et al. 1998) . Overexpression of Phox2a is sufficient to promote autonomic neurogenesis in vivo; however, knockout of Phox2a expression does not affect development of sympathetic neurons or chromaffin cells and only affects development of locus cereuleus (Morin et al. 1997; Stanke et al. 1999 ). This indicates that Phox2a is sufficient to promote SA development but not required. Hand2, GATA2 and GATA3 are transcription factors activated by Phox2b that control expression of noradrenergic markers including TH and DBH (Howard et al. 2000; Morikawa et al. 2005; Tsarovina et al. 2004) .
Phox2b is commonly expressed in NB and is used as a marker to detect minimal residual disease in patients following chemotherapy (Stutterheim et al. 2008 ). However, gene dosage studies of Phox2b in zebrafish revealed a dosesensitive role of Phox2b in NB tumorigenicity, where heterozygous loss or dominant negative mutations in Phox2b led to a block in SA cell differentiation and increased susceptibility to secondary transforming events in NB (Pei et al. 2013) . Correspondingly, studies in human primary tumor samples revealed that Phox2b mutations and chromosomal losses of the Phox2b loci (4p13) are early activating mutations in NB tumorigenesis (Krona et al. 2008) . Expression of known NB Phox2B variants within immature chick sympathetic neurons led to increased cell proliferation and dedifferentiation confirming the role Phox2B has in normal sympathoadrenal development as well as insights into its mechanism in NB tumorigenesis (Reiff et al. 2010) . Using the MHH-NB-11 xenograft model, knockdown of Phox2b within cell lines derived from metastatic foci led to increased primary tumor and micrometastatic burden when re-transplated into mice indicating the importance of Phox2b as a suppressor of tumor progression and metastasis (Naftali et al. 2016) . Taken together, Phox2b functions as a suppressor of NB tumorigenesis in a dose dependent manner and partial loss of Phox2b represents a susceptibility to NB initiation. Phox2a, Hand2 and GATA 2/ 3 have all been investigated in NB but there are no clear indications of their function in relation to tumorigenicity or a block in differentiation.
Role of MYCN in SA development and NB initiation
As mentioned previously, MYCN amplification was identified in NB over 30 years ago. It remains one of the strongest indicators of poor prognosis in high-risk NB, thought to be due to maintenance of tumors in an undifferentiated or poorly differentiated state (Seeger et al. 1985) . In NC development, while c-Myc is involved in the maintenance of multipotent NC progenitors, transient expression of MYCN stimulates ventral migration of NC and promotes differentiation of sympathetic neurons (Wakamatsu et al. 1997 ). Overexpression of MYCN, a common model for NB initiation, has vastly different effects compared with transient exposure.
Transgenic mouse models of NB have been developed using MYCN driven by the promoter for tyrosine hydroxylase (TH-MYCN), an enzyme involved in dopamine synthesis that expressed in the early migrating SA precursors of the adrenal gland and sympathetic ganglia. Homozygous TH-MYCN transgenic mice develop rampant abdominal and paraspinal NB tumors with high penetrance by 2 months of age (Weiss et al. 1997) . Sympathetic ganglia from non-transgenic and TH-MYCN mice showed significant peri-natal neuroblasts hyperplasia that regressed in the absence of MYCN expression but persisted and led to tumor formation within TH-MYCN mice, indicating the importance of peri-natal MYCN expression in the initiation of NB (Hansford et al. 2004 ).
However, expression of MYCN within SA progenitors cultured from the adrenal glands of postnatal day 0/1 mice induced proliferation and neuronal differentiation, as seen previously but was not sufficient to promote tumorigenesis (Mobley et al. 2015) . Taken together, these data suggest that NB initiation occurs embryonically during early migration or SA speciation and requires continued peri-natal expression of MYCN to drive tumorigenesis. Expression of MYCN in JoMa1, a transgenic precursor NC cell line, was sufficient to drive tumor formation in a xenograft mouse model (Schulte et al. 2013) . Further evidence of this embryologic tumorigenicity comes from overexpression of MYCN within primary NCCs generated from the mouse neural tube, where transformed truncal NCC explants resulted in robust generation of tumors that histologically and molecularly represent MYCN amplified NB (Olsen et al. 2017 ).
Summary of NC development & NB
Studies of NB initiation using MYCN as a driver indicate that initiating mutations likely occur during NC development leading to developmental arrest. NC development is a tightly regulated process of coordinated expression of both proproliferative and pro-differentiation factors (summarized in Table 1 ). The pathways that promote stemness (FGF/STAT3, c-Myc/ID3) and differentiation (BMP, FoxD3, Phox2b) have well-documented dysregulation in NB. Activation or repression of these pathways in NB likely contribute the development and maintenance of NB CSCs.
Cancer stem cells -controversy and definitions
Origin of CSC model
It has long been thought that tumors retain features and pathways of normal embryologic development, where early studies of teratomas revealed striking similarities to embryologic tissue (Conheim 1875) . The more modern view on tumor development is that a tumor retains the hierarchical structure similar to its tissue of origin, with tumor Bstem cells^that give rise to more differentiated tissues within the tumor, first proposed from evidence of multipotent tumor cells in testicular carcinomas (Kleinsmith and Pierce 1964; Pierce 1977; Pierce and Dixon 1959) . With the advancement of fluorescenceautomated cell sorting technology, investigators were first able to distinctly identify a tumor developmental hierarchy in studies of acute myelogenous leukemia, with CD34+ CD38− leukemia-initiating cells mirroring the function of hematopoietic stem cells in normal blood development and maturation (Cashman et al. 1997; Lapidot et al. 1994) . Subsequent studies in solid tumors found CSC subpopulations in many solid tumors including those in brain, breast, colon, lung, pancreatic and prostate cancers (Al-Hajj et al. 2003; Collins et al. 2005; Eramo et al. 2008; Hermann et al. 2007; O'Brien et al. 2007; Singh et al. 2004) .
A formal definition of a CSC is a tumor subpopulation that can self-renew and generate differentiated progeny that recapitulate the heterogeneous tumor of origin (Clarke et al. 2006) . One working CSC model is that, within a tumor, a small subset of cells has the capacity to both divide and to expand the reservoir of CSCs as well as differentiate into the nontumorigenic cancer cells that make up the bulk of the tumor. These CSCs have been found to be relatively refractory to modern cancer treatments including both chemotherapy and radiation through multiple mechanisms including repression of apoptosis, induced dormancy, upregulated DNA damage repair and altered drug responses (Dean 2005) . The ability to escape conventional radiation and chemotherapy may allow outgrowth of highly tumorigenic, drug-resistant clones leading to refractory disease and relapse. Targeting CSCs is a major movement in cancer research to develop better Marchant et al. 1998; Stottmann and Klingensmith 2011; Leung et al. 2016; 2 Sumantran et al. 2003; Du and Yip 2010; 3 Furthauer et al. 1997; Hong et al. 2008; Mayor et al. 1997; Monsoro-Burq et al. 2003; Wilson et al. 2000; 4 Nichane et al. 2010; 5 Agarwal et al. 2015; Odate et al. 2017; Yco et al. 2014; 6 Abu-Elmagd et al. 2006; Chang and Hemmati-Brivanlou 1998; Garcia-Castro et al. 2002; Leung et al. 2016; Tan et al. 2001; 7 Vangipuram et al. 2012; 8 Cornell and Eisen 2000; Cornell and Eisen 2002; Hernandez-Lagunas et al. 2011; 9 Chang et al. 2010; Grynfeld et al. 2000; Ferrari-Toninelli et al. 2010; Liu et al. 2017; 10 de Croze et al. 2011; 11 Li et al. 2009; 12 Liu et al. 2004; 13 Revet et al. 2008; Revet et al. 2010; 14 Monsoro-Burq et al. 2005; Plouhinec et al. 2014; 15 Fang et al. 2014; 16 Kee and Bronner-Fraser 2005; Light et al. 2005; 17 Seeger et al. 1985; Cotterman and Knoepfler 2009; Hasan et al. 2013; Selmi et al. 2015 Lo et al. 1998; Morin et al. 1997; Stanke et al. 1999;  27 Huber et al. 2005; Pattyn et al. 1999; 28 Krona et al. 2008; Pei et al. 2013; Naftali et al. 2016; Reiff et al. 2010; 29 Guillemot and Joyner 1993; Hirsch et al. 1998; 30 Howard et al. 2000; Morikawa et al. 2005; 31 Tsarovina et al. 2004 combination therapies that can effectively treat heterogeneous tumor populations and fully eliminate disease. However, to effectively target CSCs, we must first be able to clearly and accurately identify them.
Identifying and assaying CSCs
CSCs are generally identified by restricted expression of surface markers, combinations of surface markers, or by properties intrinsic to the cells (i.e., ability to exclude Hoechst dye through expression of drug efflux pumps).
In vivo analysis of CSCs
The cardinal property for identification of a CSC subpopulation is self-renewal, which can be tested rigorously only through in vivo serial re-implantation experiments to measure asymmetric division, proliferation of subpopulations, and long-term clonal growth (Kreso and Dick 2014) . In this assay, purified populations of CSCs are injected into either syngeneic or immunocompromised animals and allowed to form tumors. Tumors are then removed, disassociated, re-purified into CSC and non-CSC fractions and re-implanted into new animals to assay continued tumor formation (McCauley and Guasch 2013) . This assay rigorously tests the ability of a CSC subpopulation to give rise to a complete heterogeneous tumor, as well as the ability of CSCs self-renew and have continued long-term clonal growth. Other in vivo assays include limiting dilution experiments to assay tumorigenicity and lineage tracing to assay clonality and asymmetric growth. In limiting dilution assays, pure populations of prospective tumor-initiating cells are injected into syngeneic or immunocompromised animals in increasing amounts to calculate the tumor-initiating frequency based on the proportion of animals that develop tumors (Blackburn et al. 2011; Dick et al. 1997) . Lineage tracing experiments using fluorescent or chromogenic reporters allow investigators to track the portions of tumors that arise from CSC subpopulations (asymmetric growth and clonal expansion) (Humphries et al. 2013; Wuidart et al. 2016 ).
In vitro analysis of CSCs
In vitro assays represent a convenient way to screen for phenotypes of tumor-initiating subpopulations; however, they lack the power and utility of in vivo assays, which are the gold standard for defining CSC subpopulations. Proliferation assays can be used to investigate the growth advantage and chemoresistance. The MTT assay is a simple method to quantify the ability of cells to reduce tetrazolium salts to purple formazan product. This method measures the metabolic viability of cells and is used as a surrogate way to measure cell proliferation (Mosmann 1983) . True measurement of proliferation can be done by staining cells or tissues with Ki67 or bromodeoxyuridine (BrdU), markers of proliferating cells that correlate with ribosomal RNA synthesis and DNA replication, respectively (Kee et al. 2002) . Soft agar colony formation assays are well-characterized methods for assaying anchorage-independent cell growth, measuring the ability of cells to grow and divide independent of the surrounding environment (Borowicz et al. 2014; Puck et al. 1956 ). Soft agar assays are often used as a surrogate for in vivo studies to quantify colony formation of CSC versus non-CSC subpopulations and to test the efficacy of CSC-targeted therapeutics. However, only in vivo-limiting dilution assays, ideally with primary patient-derived cells, can directly confirm CSC subpopulations. Evidence confirming targeting strategies should also derive from in vivo approaches, as tumor heterogeneity is likely impacted by the tumor microenvironment. Tumorsphere assays represent an additional colony formation assay using the 3D spherical culture of cells within a specialized serum-free media and growth factor cocktail and may enrich for CSC subpopulations (Weiswald et al. 2015) . Tumorsphere formation and serial tumorsphere re-plating are techniques used as surrogates for in vivo re-implantation experiments. However, we emphasize that, without prior purification of specific subpopulations based on valid phenotypic markers, these assays do not directly compare tumor-initiating CSCs to 'non-CSC' subpopulations. Growth of cells in special media with ex vivo-derived cocktails of growth factors can alter the gene expression profiles of the entire cell populations independent of CSC enrichment and thus does not represent a formal identification of tumorigenicity or self-renewal (Calvet et al. 2014; Kreso and Dick 2014) . Again, CSCs and other tumor subpopulations are strongly influenced by the local tumor microenvironment, further detracting from in vitro definitions of CSC phenotypes (Bissell and Labarge 2005; Lathia et al. 2011) . While much work has focused on defining 'tumor-initiating' cell lines (TIC lines) and other CSC-like tumor-derived cell populations using surrogate in vitro assays, rigorous in vivo assays are required to validate the 'stemness' phenotype of tumor initiation subpopulations and to define their role driving tumorigenesis, metastasis and overall response to therapies.
The search for neuroblastoma CSCs
Previous markers claimed to identify neuroblastoma CSCs
Efforts to define CSCs in NB have focused on morphologies, cell efflux properties, tumorsphere culture methods and cell surface markers to label subpopulations. The majority of these studies lack the defining in vivo experiments needed to quantify differences in the tumor initiating capacity between subpopulations, prove self-renewal and confirm recapitulation of a complex tumor from a limiting number of cells (summarized in Table 2 ).
The earliest studies into the aggressive nature of high-risk NB identified cells with distinct morphologies. NB cells can be classified as N-type (neuroblastic), S-type (Schwann-like) or I-type (Intermediate) (Biedler et al. 1973) . The I-type morphology was previously characterized as a malignant NC-like, being multipotent and capable of self-renewal based on the ability to regenerate I-type cells as well as differentiate into N-and S-type morphologies (Ross et al. 1995) . Cell lines classified as I-type had 5-fold greater soft-agar plating efficiency and 6-fold greater tumor-forming capacity in SCID mice than cell lines of N-and S-type morphologies (Walton et al. 2004) . Further characterization of I-type NB cells identified a panel of genes consistently overexpressed in I-type compared to N-and S-type, including CD133 (discussed below) as well as other 'stemness' markers, KIT, NOTCH1, GPRC5C, PIGF2 and TRKB (Ross et al. 2015) . However, Itype cells do not fit the definition of a CSC as they describe an entire population and likely represent an aggressive, highly plastic cell population rather than a true CSC subpopulation.
Further studies of NB CSCs involved the identification of a side population (SP), cells that exclude Hoesct dye due to the presence of drug efflux pumps that confer multi-drug resistance. In an analysis of 23 primary NB tumor specimens, 65% had an identifiable side population that represented 0.8-51% of total tumor cells. Expression of SP correlated highly with expression of drug efflux pumps ABCG2 and ABCA3 (Hirschmann-Jax et al. 2004 ). These cells were consistently phenotyped as CD45
+ and SP cells, which the authors indicate represent an early NC stem cell-like phenotype. In an analysis of paired pre-treatment and post-treatment relapse samples of NB cell lines, SP was increased in the relapsed samples as compared to their pre-treatment control (Newton et al. 2010) . While SP represents a chemoresistant subpopulation, analysis of SP in vivo tumorigenicity and differential gene expression of NC and SA markers has yet to be elucidated. Furthermore, analysis of ABCG2 as a marker of CSCs showed ABCG2 is associated with stemness in neural stem cells and has been implicated as a CSC marker; however, robust evaluation of ABCG2-mediated tumorigenicity has also yet to be elucidated (Islam et al. 2005; Xing et al. 2015) . Overall, in vivo validation of these markers as identifiers of CSC subpopulations has not been demonstrated to date.
A surface protein studied as a marker of NB CSCs is CD133, a glycoprotein with an undefined role and a commonly used CSC marker in many other solid tumors (GrosseGehling et al. 2013) . Preliminary studies into CD133 expression in NB revealed that CD133 expression correlated with lower overall survival (Tong et al. 2008 ). CD133 has also been associated with poor outcome in NB via activation of AKT pathway-mediated chemoresistance . Loss of CD133 expression by shRNA knockdown led to decreased colony formation, induced cell differentiation and suppressed proliferation via modulation of RET expression (Takenobu et al. 2011) . In vivo knockdown of CD133, via stable expression of shRNA within xenografts, led to decreased tumor size but no change in tumor initiation (Takenobu et al. 2011) . Orthotopic injection of 500 CD133 Hi 
As evidenced by Table 2 , most of the markers of NB CSCs characterized thus far describe subpopulations of cells with higher tumorigenicity as evidenced by increased tumor formation, increased metastasis, or increased chemoresistance. CD114 (in bold) is the only marker characterized that meets the majority of criteria for defining a NB CSC subpopulation. These cells have the capacity for self-renewal, proven via lineage tracing and asymmetric growth, proven by flow cytometry analysis of tumors formed from pure CD114+ cells 1 Ross et al. 1995; Walton et al. 2004; Ross et al. 2015; 2 Hirschmann-Jax et al. 2004; Newton et al. 2010; 3 Xing et al. 2015; 4 Hartomo et al. 2015; Flahaut et al. 2016; 5 Hsu et al. 2013; Agarwal et al. 2015; 6 Tong et al. 2008; Takenobu et al. 2011; Cournoyer et al. 2012; Sartelet et al. 2012; 7 Cantilena et al. 2011; 8 Vieira et al. 2015 NB cells led to increased tumor formation and metastases compared to 500 CD133 Low cells, indicating an increased metastatic potential of CD133-positive cells; however, calculation of differential tumor formation capacity among the subpopulations was never completed (Cournoyer et al. 2012) . Furthermore, CD133 is only expressed in approximately 40% of NB cell lines and primary tumors and this therefore precludes its use as a universal marker of NB CSCs (Takenobu et al. 2011) . A robust evaluation of the tumor-initiating capacity (limiting dilution tumor formation assay) and self-renewal (serial re-implantation assay) is lacking and CD133 cannot be considered a robust marker of NB CSCs.
As mentioned previously, the Wnt/B-catenin pathway is critical in NC induction and is found to regulate CSC-like populations in other tumor models. Analysis of Frizzled receptor 6 (FZD6), a natural receptor for Wnt, revealed that high-risk NB patients with high Fzd6 expression had poor overall survival (Cantilena et al. 2011) . Furthermore, the Fzd6 subpopulation was found within hypoxic tumor regions, formed tumorspheres more readily and developed more aggressive tumors than its Fzd6-negative counterpart. Similarly, LGR5 is a Wnt-responsive g-protein-coupled receptor found to label various CSCs (Kemper et al. 2012; Liu et al. 2014; Nakata et al. 2013) . Analysis of LGR5 expression in NB revealed that high LGR5 expression correlated with poor eventfree survival in high-risk NB patients and LGR5 was expressed in a higher percentage of high-grade undifferentiated tumors as compared to low-grade tumors (Vieira et al. 2015) . Stimulation of LGR5 by Wnt3a ligands led to strong Wnt pathway induction and increased proliferation. Knockdown of LGR5 led to rapid induction of apoptosis independent of Wnt signaling, mediated by MEK/ERK signaling and cell cycle regulation. However, no in vivo assays have been performed to analyze the effect of FZD6 or LGR5 expressing subpopulations on self-renewal, asymmetric growth and tumor repopulation.
The aldehyde dehydrogenase family (ALDH) is involved in the biosynthesis of retinoic acid, an agent known to differentiate NB. High expression of ALDH leading to retinoic acid tolerance is thought to be a mechanism leading to resistance of retinoic acid differentiation therapy. There are 19 known ALDH isoforms and they have been found to be differentially expressed in CSC subpopulations (Marcato et al. 2011) . Researchers found that both ALDH1A2 and ALDH1A3 isoform expression correlated significantly with poor overall survival in high-risk NB patients. shRNA knockdown of ALDH1A2 reduced colony and tumorsphere formation in vitro (Hartomo et al. 2015) . Similarly, inhibition and knockout of isoform ALDH1A3 led to reduction in NB tumorinitiating cells (TICs) as demonstrated by reduced colony formation and reduced tumorsphere passaging (Flahaut et al. 2016) . However, despite these in vitro results, when ALDH1 2A kn ock down cell lines we re in jecte d subcutaneously into mice, there was no difference in tumor formation and only a slight, non-significant difference in tumor size (Hartomo et al. 2015) . These ALDH studies highlight the importance of rigorous in vivo testing of self-renewal rather than relying on tumorsphere re-passaging, which has been shown to be an unreliable predictor of stemness. A variety of other NB CSC markers have been used in panels, including the neurofilament Nestin, cytoplasmic protein GD2 and receptor tyrosine kinase c-KIT; however, demonstration of tumorigenicity using only in vitro models and/or expression within only a subset of NB cell lines and tumor specimens prevents the use of these proteins as robust markers (Walton et al. 2004; Xing et al. 2015) .
Expression of the surface receptor CD114 as a putative marker of NB CSCs
Recently, a novel NB subpopulation was characterized based on surface expression of the granulocyte colony-stimulating factor (G-CSF) receptor, also known as CD114. This G-CSF receptor-positive subpopulation (CD114+) is <1% of total NB cells and demonstrates several CSC-like characteristics (Hsu et al. 2013) . Xenograft limiting dilution assays showed that CD114+ cells are 10 times more tumorigenic than their CD114-counterparts and in vivo lineage tracing assays showed that CD114+ cells self-renew and can regenerate differentiated (CD114-) tumor progeny. Additionally, sensitive and specific flow cytometry methods detect surface expression of a CD114 subpopulation within all NB cell lines, PDXs and xenografts tested to date. Critically, this tumor subpopulation has also been detected in all the primary diagnostic NB patient samples analyzed to date (n > 30) at frequencies between 0.01 and 3%. A trend towards enrichment of the CD114+ subpopulation after chemotherapy, in tumor relapses and in metastases, indicates a level of chemoresistance within these cells (Hsu et al. 2013; Agarwal et al. 2015) . Furthermore, the CD114+ subpopulation has a gene expression profile similar to that of primitive NC cells including markers of early pre-migratory crest (SOX10, Twist) as well as mixed EMT markers (CHD1, CHD2, Vim, MMPs). Very recently, experiments using neural tube explants demonstrated transient expression of the CSF3R gene (coding for CD114) during ex vivo expansion and MYCN-driven transformation of these primitive crest precursors (K. Freeman, St Jude's Hospital, personal communication). Taken together, CD114 expression marks a NB subpopulation that is highly tumorigenic when compared directly to the CD114− subpopulation, has a stem cell-like molecular phenotype and differentiates into CD114− cells in vivo and in vitro. Additionally, this subpopulation has a gene expression profile similar to that of premigratory or early migratory NC, which has recently been shown to maintain multipotent capacity (Baggiolini et al. 2015) . Furthermore, researchers have shown that NB tumorigenicity and metastasis are dependent on this subpopulation through downstream activation of STAT3 target genes (Agarwal et al. 2015) . This tumorigenicity is abrogated through treatment with G-CSF-neutralizing antibodies or STAT3 inhibition. Further work is needed to define the role of this tumor subpopulation in neuroblastoma pathogenesis and drug responses and to determine whether targeting them will enhance current and future treatment strategies.
Advancing technology for identification and characterization of CSC subpopulations
Using computation models to predict stemness and drug targets Using a network analysis approach applied to transcriptome data, researchers at the University of Chicago identified a c-Myc-regulated stem cell-like gene network common to high-risk NB regardless of MYCN amplification status (Yang et al. 2017) . As a proof of concept, they performed a drug-gene interaction analysis for this cMyc-dependent network and identified a CDK inhibitor, Ronicinib, as a potential therapeutic. Treatment of NB cell lines with Ronicinib led to downregulation of c-Myc, cell cycle arrest and eventually cell apoptosis. Similar analyses by the same group in breast cancer models identified markers of metastasis as well as patient prognostic indicators (Yang et al. , 2014 . While this approach does not identify distinct markers of NB CSCs, per se, it can help us better understand the gene networks associated with aggressive cell subpopulations and identify potential CSC targets for the treatment of high-risk disease.
Single-cell RNA sequencing as a method for identifying tumor hierarchy and CSC subpopulations Advances in RNA sequencing technology have allowed for the analysis of single-cell transcriptomes from large populations of cells (Wang and Navin 2015) . This technology provides a huge benefit to studying heterogeneous cell populations within tumors and identifying subpopulations with stem-like gene signatures and enrichments (Cloney 2017) . Single-cell RNA-sequencing of 430 cells from five different glioblastoma specimens showed marked intratumoral heterogeneity in the transcription of genes related to activated signaling, proliferation, immune Fig. 1 Neural crest development and neuroblastoma pathogenesis. NC development is a tightly regulated process beginning with neural tube formation and ending with the formation of terminally differentiated NC derivatives, including the sympathoadrenal lineages. Each step of the process is controlled by cascades of signaling pathways and activation of key transcription factors. The exact stage along this pathway where NB originates still remains unknown; however, the highlighted key pathways have been shown to contribute to 'stemness' and may be involved in the formation of tumor-initiating NB CSCs response and hypoxic response (Patel et al. 2014) . In a large-scale analysis of 4347 single-cell transcriptome libraries from six oligodendroglioma specimens, researchers at the Broad Institute discovered clustering of a subpopulation with increased stem cell expression signatures (high SOX2/4/11, cell cyclins). These cells had increased proliferative potential and self-renewal gene signatures, providing evidence for a developmental hiera r c h y a n d C S C m o d e l i n t h e b r a i n t u m o r oligodendroglioma (Tirosh et al. 2016) . Whole-tumor single-cell RNA-seq would allow us to identify the developmental hierarchy that exists in NB and better identify gene networks activated in NB CSCs (Fig. 1) .
Conclusion
Under genetic, epigenetic or chemical pressure, the normal developmental pathways in NC cells become dysregulated leading to NB tumor initiation (Louis and Shohet 2015) . Under the pressure of oncogenic stimuli such as aberrant expression of MYCN, dysregulation of NC pathways may generate highly malignant NB CSC subpopulations. Among different NB CSC markers studied, expression of the G-CSF receptor (CD114) labels a tumor subpopulation meeting many of the criteria for CSCs. These include (1) self-renewal, (2) high tumor initiation potential and (3) differentiation capacity to generate primarily CD114− complex tumors, as defined by in vivo-limiting dilution and lineage tracing studies. Longterm serial transplantation comparisons of CD114− and CD114+ subpopulations remain to be performed from primary tumor tissue. Importantly, we found that this subpopulation is consistently represented in all primary tumor samples tested today (n> 30). Human CD114+ neuroblastoma cells have distinct genetic and epigenetic signatures similar to early neural crest, further highlighting the role of NC development as a source of tumor heterogeneity and potential tumor-initiating CSCs. Ongoing research efforts will determine the precise development switches in NC differentiation pathways that define tumor-initiating populations. These include more rigorous in vivo testing of putative CSC markers and improvement in technology for characterizing tumor hierarchy and gene expression patterns. 
